StreetInsider.com News Articles

Form 144 Janux Therapeutics, Inc. Filed by: Doyle Janeen Noel

Tue, 02 Jun 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20260602/26593608.html

Form 144 Janux Therapeutics, Inc. Filed by: Doyle Janeen Noel

Tue, 02 Jun 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20260602/26593608.html

Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: JANUS HENDERSON GROUP PLC

Fri, 15 May 2026 12:39:00 -0400

si-local-file:///var/storage/secattach/20260515/26502889.html

Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: JANUS HENDERSON GROUP PLC

Fri, 15 May 2026 12:39:00 -0400

si-local-file:///var/storage/secattach/20260515/26502889.html

Form 4 Janux Therapeutics, Inc. For: May 11 Filed by: Dobek Maria

Wed, 13 May 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260513/26488025.html

Form 4 Janux Therapeutics, Inc. For: May 11 Filed by: Dobek Maria

Wed, 13 May 2026 20:00:00 -0400

si-local-file:///var/storage/secattach/20260513/26488025.html

Form SCHEDULE 13G Janux Therapeutics, Inc. Filed by: STATE STREET CORP

Tue, 12 May 2026 11:19:00 -0400

si-local-file:///var/storage/secattach/20260512/26475575.html

Form SCHEDULE 13G Janux Therapeutics, Inc. Filed by: STATE STREET CORP

Tue, 12 May 2026 11:19:00 -0400

si-local-file:///var/storage/secattach/20260512/26475575.html

Janux Therapeutics (JANX) PT Lowered to $60 at Cantor Fitzgerald

Fri, 08 May 2026 08:07:42 -0400

Cantor Fitzgerald analyst Josh Schimmer lowered the price target on Janux Therapeutics (NASDAQ: JANX) to $60.00 (from $100.00) while maintaining a Overweight rating.

Janux Therapeutics (JANX) PT Lowered to $26 at Piper Sandler

Fri, 08 May 2026 07:58:04 -0400

Piper Sandler analyst Kelsey Goodwin lowered the price target on Janux Therapeutics (NASDAQ: JANX) to $26.00 (from $30.00) while maintaining a Overweight rating.

Janux Therapeutics (JANX) PT Lowered to $58 at Guggenheim

Fri, 08 May 2026 07:22:25 -0400

Guggenheim analyst Brad Canino lowered the price target on Janux Therapeutics (NASDAQ: JANX) to $58.00 (from $68.00) while maintaining a Buy rating.

Janux Therapeutics, Inc. (JANX) Tops Q1 EPS by 18c

Thu, 07 May 2026 18:33:39 -0400

Janux Therapeutics, Inc. (NASDAQ: JANX) reported Q1 EPS of ($0.39), $0.18 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $3.73 million versus the consensus estimate of $4.18 million.

For earnings history and earnings-related data on Janux Therapeutics, Inc. (JANX) click here.

Form 10-Q Janux Therapeutics, Inc. For: Mar 31

Thu, 07 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260507/26454398.html

Form 10-Q Janux Therapeutics, Inc. For: Mar 31

Thu, 07 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260507/26454398.html

Form 8-K Janux Therapeutics, Inc. For: May 07

Thu, 07 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260507/26453686.html

Form 8-K Janux Therapeutics, Inc. For: May 07

Thu, 07 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260507/26453686.html

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Thu, 07 May 2026 16:01:00 -0400

JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide
Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate
JANX011 Phase 1 study ongoing in healthy volunteers
Discontinued development of JANX008 following completion of Phase 1a
Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment
Strong cash position supporting continued pipeline execution

SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended March 31, 2026, and provided a business update.

"Our commitment to advancing a prostate

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Thu, 07 May 2026 16:01:00 -0400

JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide
Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate
JANX011 Phase 1 study ongoing in healthy volunteers
Discontinued development of JANX008 following completion of Phase 1a
Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment
Strong cash position supporting continued pipeline execution

"Our commitment to advancing a prostate

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Thu, 07 May 2026 16:01:00 -0400

JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide
Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate
JANX011 Phase 1 study ongoing in healthy volunteers
Discontinued development of JANX008 following completion of Phase 1a
Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment
Strong cash position supporting continued pipeline execution

"Our commitment to advancing a prostate

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Thu, 07 May 2026 16:01:00 -0400

JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide
Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate
JANX011 Phase 1 study ongoing in healthy volunteers
Discontinued development of JANX008 following completion of Phase 1a
Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment
Strong cash position supporting continued pipeline execution

"Our commitment to advancing a prostate

Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: FMR LLC

Wed, 06 May 2026 11:24:00 -0400

si-local-file:///var/storage/secattach/20260506/26441580.html

Form SCHEDULE 13G/A Janux Therapeutics, Inc. Filed by: FMR LLC

Wed, 06 May 2026 11:24:00 -0400

si-local-file:///var/storage/secattach/20260506/26441580.html

Form SCHEDULE 13G Janux Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.

Wed, 29 Apr 2026 17:32:00 -0400

si-local-file:///var/storage/secattach/20260429/26397165.html

Form SCHEDULE 13G Janux Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.

Wed, 29 Apr 2026 17:32:00 -0400

si-local-file:///var/storage/secattach/20260429/26397165.html

Form SCHEDULE 13G Janux Therapeutics, Inc. Filed by: Point72 Asset Management, L.P.

Wed, 29 Apr 2026 17:31:00 -0400

si-local-file:///var/storage/secattach/20260429/26397157.html